Alnylam Pharmaceuticals, Inc. or ADMA Biologics, Inc.: Who Leads in Yearly Revenue?

Biotech Giants: Alnylam vs. ADMA in Revenue Growth

__timestampADMA Biologics, Inc.Alnylam Pharmaceuticals, Inc.
Wednesday, January 1, 2014591554550561000
Thursday, January 1, 2015717763341097000
Friday, January 1, 20161066103747159000
Sunday, January 1, 20172276056089912000
Monday, January 1, 20181698529074908000
Tuesday, January 1, 201929349083219750000
Wednesday, January 1, 202042219783492853000
Friday, January 1, 202180942625844287000
Saturday, January 1, 20221540796921037418000
Sunday, January 1, 20232582149991828292000
Monday, January 1, 20242248243000
Loading chart...

Unleashing insights

Alnylam Pharmaceuticals vs. ADMA Biologics: A Revenue Showdown

In the competitive landscape of biotechnology, Alnylam Pharmaceuticals and ADMA Biologics have been vying for dominance in yearly revenue. Since 2014, Alnylam has consistently outpaced ADMA, showcasing a remarkable growth trajectory. By 2023, Alnylam's revenue surged to nearly 1.83 billion, a staggering 3,500% increase from its 2014 figures. In contrast, ADMA Biologics, while showing impressive growth, reached 258 million in 2023, marking a 4,300% increase from 2014. This data highlights Alnylam's strategic advancements in RNA interference therapeutics, which have propelled its financial success. Meanwhile, ADMA's focus on immunoglobulin therapies has also yielded significant revenue growth, albeit at a smaller scale. As the biotech industry continues to evolve, these companies exemplify the dynamic nature of innovation-driven revenue growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025